Prosonix, a specialty pharmaceutical company developing a portfolio of inhaled respiratory drugs, has entered into a global licensing agreement with Mylan Inc. for the company’s inhaled respiratory products, PSX1001 and PSX1050.  

PSX1001 and PSX1050 are the first products from Prosonix’s proprietary particle engineering platform and are being developed as generic versions to GlaxoSmithKline’s pressurized metered dose inhalers (pMDI) Flixotide^® and Flovent^®, respectively. Flixotide and Flovent contain the active ingredient fluticasone propionate, an inhaled corticosteroid, and are indicated for the treatment of asthma. A first marketing authorization application for PSX1001 is expected to be submitted in the European Union (EU) in 2014.

Under the terms of the licensing agreement, Prosonix will file PSX1001 in the EU and retain marketing rights in certain territories. Mylan has marketing rights for PSX1001 and PSX1050 in the US, Canada, Australia, New Zealand, India, Japan, the EU, Iceland, Liechtenstein, Norway, Switzerland, Turkey, Russian Federation, and the Commonwealth of Independent States. All other terms of the agreement remain confidential.

Source: Mylan Inc.